Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Birinapant

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Birinapant?

Birinapant is an investigational drug.

There have been 12 clinical trials for Birinapant. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2012.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Fallopian Tube Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are TetraLogic Pharmaceuticals, National Cancer Institute (NCI), and Jonsson Comprehensive Cancer Center.

There are four US patents protecting this investigational drug and thirty-one international patents.

Recent Clinical Trials for Birinapant
Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI)Phase 1
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI)Phase 1
Dose-escalation Study of Birinapant and Pembrolizumab in Solid TumorsMerck Sharp & Dohme Corp.Phase 1/Phase 2

See all Birinapant clinical trials

Clinical Trial Summary for Birinapant

Top disease conditions for Birinapant
Top clinical trial sponsors for Birinapant

See all Birinapant clinical trials

US Patents for Birinapant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Birinapant   Start Trial SMAC Mimetic TetraLogic Birinapant UK Ltd. (Birmingham, GB)   Start Trial
Birinapant   Start Trial SMAC mimetic Medivir AB (Huddinge, SE)   Start Trial
Birinapant   Start Trial 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic TetraLogic Pharmaceuticals Corp. (Malvern, PA)   Start Trial
Birinapant   Start Trial SMAC mimetic for treating myelodysplastic syndromes TetraLogic Pharmaceuticals Corporation (Malvern, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Birinapant

Drugname Country Document Number Estimated Expiration Related US Patent
Birinapant African Regional IP Organization (ARIPO) 3619 2029-07-02   Start Trial
Birinapant Argentina 077629 2029-07-02   Start Trial
Birinapant Australia 2010266525 2029-07-02   Start Trial
Birinapant Brazil PI1013958 2029-07-02   Start Trial
Birinapant Canada 2766162 2029-07-02   Start Trial
Birinapant China 102471275 2029-07-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.